FENC Fennec Pharma: Earnings per share for the last 12 months

Fennec Pharmaceuticals Inc (FENC) - corporate logo

Fennec Pharmaceuticals (FENC) specializes in developing agents that prevent chemotherapy-induced hearing loss. The business relies on high macro-resilience and a lack of seasonality due to strict medical protocols and insurance. Massive scaling potential allows a single successful development to fully offset R&D costs. The current EPS is 112.10. The price action on this chart underscores the dominance of the PEDMARK drug in the pediatric niche and a steady influx of new clinics.

Fennec Pharmaceuticals Inc (FENC) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/15/2026

FENC (Fennec Pharma): analytical breakdowns and indicator data

- price and consensus price forecast:
Market Price Fennec Pharma|FENC - Price Target Chart
- company stock capitalization data:
Market Capitalization Fennec Pharmaceuticals Inc|FENC - Enterprise Value
- book capitalization indicators:
Accounting Value per Share Fennec Pharmaceuticals|FENC - Company Book Value|Market-to-Book Ratio fennecpharma.com|FENC - Aggregate Company Assets
- company total debt and liquidity indicators:
Debt to Equity Fennec Pharmaceuticals|FENC - Long-Term Debt to Equity|Current Liabilities to Capital Fennec Pharmaceuticals|FENC - Company Aggregate Debts|Debt to Net Assets Fennec Pharmaceuticals|FENC - Company Long-Term Liabilities|Short-Term Debt Fennec Pharmaceuticals|Intermediate Coverage Ratio fennecpharma.com
- earnings and market multiples details:
FENC - Net Income|Future Net Profit Fennec Pharmaceuticals|FENC - P/E Multiple|Future Price to Earnings Multiple Fennec Pharmaceuticals Inc|FENC - PEG Multiple|Company Value to EBITDA Fennec|FENC - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Fennec Pharmaceuticals|FENC - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth fennecpharma.com|FENC - Earnings per share growth in current year|Net earnings per share change forecast for next year Fennec Pharmaceuticals
- revenue and sales details:
FENC - Company Sales|Company Expected Sales Volume Fennec Pharmaceuticals Inc.|FENC - P/S Multiple|Future Price to Revenue Fennec Pharmaceuticals Inc|FENC - Sales Growth YoY (TTM)
Fundamental company valuation:FENC Fennec Pharmaceuticals Inc
Flagship merchandise of Fennec Pharmaceuticals Inc.

Investors are assessing the stability of Fennec Pharmaceuticals (FENC) through the business's ability to generate sustainable cash flow. This indicator measures the percentage change in net income per share over the last twelve months relative to the same period last year. By analyzing the EPS YoY TTM growth rate, one can determine the commercialization efficiency of the drug Pedmark within pediatric protocols. Positive momentum confirms the monetization of a unique hearing protection niche and the fundamental resilience of the company.

Direct competitors

Net earnings per one share for the last twelve months Incyte Corp|HCM: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NUVB|DAWN (dayonebio.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months monopartx.com (MNPR)|Earnings per share for the last twelve months Inhibrx Corp (INBX)|IMAB - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics Inc HRTX|Nuvectis Pharma, Inc - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BeyondSpring Pharma BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Lixte Biotechnology LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals Inc.)|CLRB (Cellectar Biosciences, Inc.) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (Can-Fite BioPharma Ltd.)|Aprea Therapeutics, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (kaziatherapeutics.com)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana Corp (NCNA)|Earnings per share for the last twelve months Chimerix|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Corporation (KRON)|Earnings per share for the last twelve months Kintara KTRA|ONCT (Oncternal Therapeutics, Inc.) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months